ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors
GHENT, Belgium, Nov. 3, 2020 /PRNewswire/ --ExeVir, which is developingnanobody therapiesproviding broad protection against viral infections, including a lead candidate for coronaviruses,today announced that Michel Kazatchkine and Stef Heylen have been appointed to the Board.
- GHENT, Belgium, Nov. 3, 2020 /PRNewswire/ --ExeVir, which is developingnanobody therapiesproviding broad protection against viral infections, including a lead candidate for coronaviruses,today announced that Michel Kazatchkine and Stef Heylen have been appointed to the Board.
- Michel Kazatchkine is Emeritus Professor of Immunology at Ren Descartes University in Paris.
- Torsten Mummenbrauer, CEO of ExeVir, said: "We are extremely pleased to welcome Michel and Stef to the Board.
- Stef Heylen, said: "ExeVir Bio isfounded on world class science and an excellent management team.